OP2 Drugs SAS ("OP2") is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in preclinical stage, with a strong scientific rational. Based on strategic partnerships in Europe and in the US, we are generatling growth and value for all stakeholders thanks to our drug candidates pipeline, in several indications. OP2 Drugs is planned to move forward to clinic in 2018. Located in Pessac, close to Bordeaux (France), OP2 Drugs is supported by Unitec (Bordeaux), managed by Frédéric Marin (CEO) and Michel Andraud (CFO), and funded by ambitious financial players.